Citi Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY)

Citi analyst David Lebowitz reiterated a Buy rating and $342.00 price target on Alnylam Pharmaceuticals (NASDAQ: ALNY).

The analyst comments "Alnylam hosted a TTR Investor Day to discuss transthyretin amyloid cardiomyopathy (ATTR-CM), highlighting disease severity, the unmet need for patients, and the outlook in this increasingly competitive market. This follows positive HELIOS-B data for Amvuttra for ATTR-CM announced earlier this year (see HERE and HERE), which suggests the drug is well-positioned to become the frontline (1L), standard of care in this mega blockbuster market. To this end, Alnylam announced the submission of its sNDA with a priority review voucher (PRV), implying an FDA decision by April 2025, with submissions for other regions expected before year-end. Assuming approval (likely without an AdCom), the team is well-prepared for launch, being commercially ready with an already established field force, patient support programs, and favorable payor dynamics."

For an analyst ratings summary and ratings history on Alnylam Pharmaceuticals click here. For more ratings news on Alnylam Pharmaceuticals click here.

Shares of Alnylam Pharmaceuticals closed at $270.90 yesterday.

You May Also Be Interested In

• Bumble Inc. (BMBL) PT Lowered to $3.20 at Citi
• Reddit to join S&P 500 index on Aug. 18, shares soar
• Navient (NAVI) Declares $0.16 Quarterly Dividend; 6.9% Yield